NOVEL SPIRO [2H-1-BENZOPYRAN-2,4'-PIPERIDINE]- 4(3H)-ONE DERIVATIVES, ACID ADDITION SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Abstract: The invention relates to novel spiro[2H-1-benzopyran-2,4'-piperidine]-4(3H)-one derivatives of formula (I), wherein R stands for halogen, nitro group or a straight or branched chain C1-6 alkyl group, and their acid addition salts, as well as their quaternary salts of formula (Ia), wherein R and R' are the same or different and are identical to the meaning of said (above) R or can mean also hydrogen; and Z<-> represents one equivalent of an anion. The compounds of formulas (I) and (Ia) exert an improving effect on dementias of various pathological origin and accompanying symptoms thereof. Furthermore, the invention relates to a process for the preparation of compounds of formulas (I) and (Ia); to pharmaceutical compositions containing as active agents the above compounds of formulas (I) and (Ia); and to a method of treatment.

Description: NOVEL SPIRO H-l-BENZOPYRAN-Z^'-PIPERTOINEl^CSrTj-ONE DERIVATIVES, ACID ADDITION SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM The invention relates to novel spιro[2H-l-benzopyran-2,4'-pιpeπdιne]-4(3H)-one deπvatives of formula (I), wherein R stands for halogen, nitro group or a straight or branched chain C ι- 6 alkyl group, and their acid addition salts, as well as their quaternary salts of formula (Ia), wherein R and R' are the same or different and are identical to the meaning of said (above) R or can mean also hydrogen; and Z ' represents one equivalent of an anion The above compounds and salts exert a favourably influencing effect on dementias of various pathological ongm or associated (accompanying) symptoms, respectively, thereof The invention also relates to pharmaceutical compositions containing as active ingredients novel or, wherein R means hydrogen, known spιro[2H-l-benzopyran-2,4'- pιpeπdιne]-4(3H)-one deπvatives of formula (I) and/or pharmaceutically acceptable salts, and/or quaternary salts thereof of formula (Ia) These compositions favourably influence the dementias of vaπous pathological ongm or accompanying symptoms, respectively, thereof Furthermore, the invention relates to the process of preparation of compounds of the formulas (I) and (Ia) The invention relates also to a method of treatment, which compπses administeπng to a mammal, including man to be treated one or more effective dose(s) of a compound of formula (I) and/or pharmaceutically acceptable salts, and/or quaternary salts thereof of formula (Ia) for alleviating dementias of vaπous pathological origin or the accompanying (associated) symptoms thereof Disturbances of various degree and progression of mental and cognitive functions (such as learning, memory, faculty of judgement and abstraction) are common characteπstics of the dementias of various pathological oπgin, e g .Alzheimer's disease, multπnfarct dementias, states following stroke, dementias associated with Parkinson's disease or Huntington's chorea, or dementias occurπng as sequels of hypoxia or poisonings Since the life quality of both the patient and his surroundings are decisively determined by the integrity of psychic, mental and cognitive functions (learning, memory), one of the most important targets of the therapy of dementias of vaπous aetiology is to prevent the impairment of the cognitive functions and to reverse the disturbances established and their sequels It has surpπsmgly been found that the spιro[2H-l-benzopyran-2,4'-ριpeπdιne]-4(3H)- one deπvatives of formulas (I) and (la) possess a significant antiamnesic effect l'-Benzylspιro[2H-l-benzopyran-2,4'-pιpeπdιne]-4(3H)-one of formula (I) containing hydrogen as R as well as some of its deπvatives were descπbed [Chem Pharm Bull 29, 3494- 3497 (1981)] These compounds were investigated as inhibitors of the release of histamme from mast cells m compaπson to disodium chromoglycate [chemically l,3-bιs(2-carboxy-4- oxochromen-5-yloxy)propan-2-ol disodium salt] l'-Benzylspiro[2H-l-benzopyran-2,4'- pιpeπdιne]-4(3H)-one was prepared by boiling l-benzyl-4-pιpeπdone with 2-hydroxy- acetophenone under reflux in methanolic medium in the presence of pyrrolidine A reaction of similar type had previously been earned out between certain ketones and 2- hydroxyacetophenone in toluene by the addition of pyrrolidine [Synthesis 886 (1978)] An advantageous feature of the method consists in that the water formed duπng the cyclocondensation may azeotropically be distilled off According to the Chem Pharm Bull publication cited above, the melting point of 1 '- benzylspιro[2H-l-benzopyran-2,4'-pιpeπdιne]-4(3H)-one of formula (I) containing hydrogen as R is at 91-93°C However, it has been shown in our reproduction expeπments directed to the preparation of this compound, that its melting point was about by 10°C higher (103-104°C) in each case and indepedently thereof that it was prepared by process a) or b) This observation may be explained by a high-grade contamination or a chemical structure different from the published one of the compound descπbed in the literature A much more wide scope of spπo[2H-l-benzopyran-2.4'-pιpeπdme]-4(3H)-one derivatives are concerned by the European patent application No 0,431,943 A2 relating to antiarrhythmic agents of III class A very broad variety of target compounds according to this patent document are defined on the basis of general formulas, teachings by name are given only to a much more restπcted scope of these compounds Their compounds illustrated, which are structurally close to the target compounds of our invention, are characteπstically distinct from those of our invention from the view point of substituents In general, they are characteπzed by a substituent (e g methanesulfonylamino, methoxy, methylthio, dimethylamino or acetamido group) in position 6 of the πng system They are similarly characterized thereof that the - j - aromatic substituent (if present) is connected to the nitrogen through an alkyl chain containing at least two atoms The most closely related compound disclosed is l'-[2-(p-nιtrophenyl)ethyl]- spιro[2H-l-benzopyran-2,4'-pιpeπdιne]-4(3H)-one hydrochloπde hemihyd-rate (Example 68) No specific pharmacological results are descπbed in this patent application The really effective substances of the bulky content of this patent document are emphasized in J Med Chem 35 . 3973 (1992), these are common 6-methanesulfonylamιno deπvatives and bear 2-aryl-ethyl or 2-heteroarylethyl substituent on nitrogen in every case Only one single deπvative is nominated, which does not contain any substituent in position 6, which is however an l'-2-(2-pyπdyl)ethyl] deπvative It can be stated from those descnbed above that, from compounds of formula (I), 1'- benzylspιro[2H-l-benzopyran-2,4'-pιpeπdιne]-4(3H)-one containing hydrogen as R is only known (if the melting point deviation mentioned above is not considered), but its quaternary deπvative of formula (Ia) is also novel Based on the revealed therapeutical effects of known, structurally related compounds it could not be expected that compounds of formulas (I) and (Ia) could have a favourable influence on dementias of vaπous pathological oπgin or the accompanying symptoms thereof According to the invention, the compounds of formulas (I) and (Ia) are prepared by a) reacting o-hydroxyacetophenone with an N-(p-substιtuted benzyl)-4-pιpeπdone of formula (II), wherein R stands for halogen or nitro group or a straight or branched chain Cι^ alkyl group in the presence of pyrolhdine, or b) alkylating spιro[2H-l-benzopyran-2,4'-pιpeπdιne]-4(3H)-one of formula (IV) with a p-substituted benzyl halide of formula (III), wherein R means halogen or nitro group or a straight or branched chain Cι. 0 alkyl group and X means chloπne or bromine, in the presence of an acid binding agent, then if desired, converting a spιro[2H-l-benzopyran-2,4'-pιpeπdιne]-4(3H)-one derivative of formula (I), wherein R means halogen or nitro group or a straight or branched chain Cue alkyl group, obtained as a base, to its acid addition salt by treating it with an acid, and/or, if desired, liberating the base form of a spιro[2H-l-benzopyran-2,4'-pιpeπdme]-4(3H)-one derivative of formula (I) wherein R means halogen or nitro group or a straight or branched chain C \ . 0 alkyl group obtained as an acid addition salt, by treating it with a base, or c) quaternizing a spιro[2H-l-benzopyran-2,4'-pιpeπdιne]-4(3H)-one derivative of formula (IV) or an acid addition salt thereof, or a spιro[2H-l-benzopyran-2,4'-pιpeπdme]- 4(3H)-one deπvatne of formula (I) or an acid addition salt thereof wherein R means hydrogen, halogen, nitro group or a straight or branched chain Cj.6 alkyl group, with a benzyl halide of formula (III), wherein R means hydrogen, halogen or nitro group or a straight or branched chain alkyl group, and X represents chlorine or bromine, to obtain quaternary salts of formula (Ia), wherein R and R are the same or different and are identical to said R but can mean also hydrogen, and Z " means one equivalent of an anion The hydrogen maleate salt of the known compound of formula (I) containing hydrogen as R is novel. The advantage of this salt over the free base form appears in the higher stability A common and definitive feature of cognition-enhancing, I e nootropic drugs occurs in their capability to enhance the resistance of learning and memory processes against influences inducing anterograde and retrograde amnesia Impairment of learning and memory induced by vaπous ways, e g by antichohnergic drugs (such as scopolamine), carbon dioxide poisoning, a high dose of an anxiolytic agent (such as diazepam) or electroshock are commonly accepted expeπmental animal models of memory and learning deficiencies developed in human disorders of vaπous aetiology (such as Alzheimer's disease, parlαnsonism, Huntington's chorea or vascular dementias and states after stroke accompanied by neurodegenerative injunes) It has been found that compounds of formulas (I) and (Ia) exert an excellent antiamnesic effect in these animal models and therefore, they are useful for the treatment of cognitive disturbances occurnng in the diseases mentioned above The biological activity of the compounds of formulas (I) and (Ia) was studied by using passive avoidance test This test is one of the most widely used animal expenmental model for investigating the effects of substances on the cognitive functions (learning and memory processes) This is based on inhibition of the genetically determined behaviour of rodents (mice and rats) that they prefer dark space to light one A single electnc shock given in the dark box is employed as a memory trace, the retention and retrieval of which can be controlled after a shorter or longer period 1 Diazepam ( " DIA) induced anterograde amnesia The passive avoidance test was earned out on NMRI mice with a body weight of 25-28 g During the learning, preselected animals (mice enteπng into a dark space from an illuminated space within 30 s) were placed into an illuminated space After entering into the dark space, the animal received within 30 s onto his plant an electric shock (1 mA for 3 s causing an unpleasant sensation The time of entry into the dark space (latency period) was measured During the check, after 24 hours, the animals were again put back to the illuminated space and the time elapsed until entry into the dark space (retention time) was measured (limit time = 300 s) The animals were intrapeπtoneally (i p ) treated with 3 mg/kg of diazepam (chemically, 7-chloro-l,3-dιhydro-l-methyl-5-phenyl-2H-l,4-benzodιazepιn-2-one) 30 minutes before learning in order to induce anterograde amnesia The compounds were orally (p o ) administered in doses of 0 1 or 10 mg/kg, respectively one hour before the learning The protective effect was calculated as percentage value (p%) by using the following formula Ttreated - DIA " Tpljcebo + DIA p% = x 100 <■ placebo " 1 placebo - DIA 2 Electroshock (ECS-) induced retrograde amnesia In this test, the retrograde amnesia was induced on NMRI mice having a body weight of 24-26 g by using an auπcular electroshock treatment of 20 mA for 0 2 s at one hour following the learning The compounds to be tested were administered 2 hours after learning The protective effect was calculated as percentage value (p%) by using the following formula Ttreated -ECS " ljcebo +ECS p% = x 100 L placebo " Tplacebo - ECS In the above formulas, T means the measured retention time of animals treated as shown in the index or the measured retention time of untreated animals, respectively The results of expeπments are summaπzed in the following Tables Table I Effect of spιro[2H-l-benzopyran-2,4'-pφeπdιne]-4(3H)-one deπvatives on the diazepam induced anterograde amnesia Compound Dose(mg/kgp o) Prevention% 4600592 01 144* 10 92 4610351 01 78 10 176* 4611109 01 92 10 0 4610282 01 131* 10 24 4610350 0.1 170* 10 29 461 1265 0 1 86* 10 134* 461 1266 0.1 159* 10 105* 461 1267 0.1 47 10 67* Vinpocetme 0.1 0 10 123 * = p < 0.05 by the Mann-Whitney test in compaπson to the diazepam control group. Table 2 Effect of spiro[2H-l-benzopyran-2,4'-pιperidine]-4(3H)-one derivatives on the electroshock induced retrograde amnesia It can be seen from data of the Tables that the compounds of formulas (I) and (Ia) proved to be very effective in the diazepam-induced anterograde amnesia test of the so-called "one tπal step-through passive avoidance" experiment, a method useful for measuring cognitive functions. The effects of compounds of the present invention were compared to those of drugs successfully employed in the therapy From the compounds, those of code numbers 4600592, -•S102S2, 461035 1. -Y Y359. 46 Y 255 and J61 Ϊ266 significantly (in a percentage of 105-1 76 %) antagonized the amnesic effect of diazepam Analogues containing bromine or nitro group as substituent (compounds 4611109 and 4610350) showed an antiamnesic action in lower doses (0 1 mg/kg) but were inactive in higher doses, while both lower doses (0 1 mg/kg) as well as higher doses (10 mg/kg) of the compounds of formulas (I) and (Ia) containing tertiary butyl group (compounds 4611266 and 461 1265) provided nearly the same protection against the amnesic effect of diazepam Three substances exhibited antiamnesic effectivity in the ECS-mduced retrograde amnesia test The compound 4610351 could significantly reverse the ECS-cauesed amnesia in both doses a significant value (108 %) was obtained by the higher dose A dose of 0 1 mg/kg of compound 4610282 provided 77 % protection No considerable protection was afforded in this test by the known compound 4600592 containing hydrogen as R It can be seen that particularly compounds 4610282, 4610350, 4610351 and 4611266 from the substances of formula (I) as well as 4611265 from the deπvatives of formula (Ia) possess a significant antiamnesic effect Compound 4610351 has been investigated in detail both under m vitro and m vivo conditions This compound exerted 36 % protection in an oral dose of 10 mg/kg in the normobaπc hypoxia-induced memory deficiency model on rats, this surpassed the protective effect of 21 % provided by 10 mg/kg oral dose of vinpocetine The same compound significantly inhibited the K ~ - or veratπne-mduced uptake of 45 Ca +* by synaptosome preparation, a fact indicating the inhibitory action of the compound on the neuronal calcium uptake with the IC 5 0 values of 45 6 μM (K " -ιnduced Ca " uptake) and 4,5 μM (veratπne-induced 5 Ca " uptake), respectively On the basis of these investigations, compounds of formulas (I) and (Ia) can be utilized for the treatment of diseases and dementias accompanied by the impairment of cognitive processes (learning, memory), such as multiinfarct and Alzheimer type dementias, states following stroke, lschaemic injuries, sequels of trauma of the central nervous system, parkinsonism, Huntington's chorea or multiple sclerosis The therapeutical doses of compounds of formulas (I) and (Ia) can be expected between 0 1 and 40 mg/kg of body weight given orally, daily once or several times Based on the statement of the prior art European patent application No 0,431 ,943 A2 and J Med Chem 3_5 3973 (1 92), according to which compounds of similar structure showed an antiarrhythmic action, our target compounds have also been tested from this viewpoint These expenments were carried out on rats (with a body weight of 180-200 g) anaesthetized by uretane ( 1 25 g/kg 1 p ) in such a way that 50 us/kg of aconiπne [chemically acetyl benzoyl aconine] was injected to the tail vein then, the arrhythmic disturbances were observed on ECG II. lead after 5 minutes [J Med. Exp. K), 93 (1964)] The compounds to be tested for antiarrhythmic effect were intravenously (l v ) administered 2 minutes, or orally one hour before aconitine (The route of administration is shown in the following Table ) The aconitine arrhythmia was evaluated in such a manner that the seventy of arrhythmia was characteπzed by an increasing number and, after average calculation both in the control as well as in the tested group, the average of treated group was expressed as percentage of the control. The arrhythmia was characteπzed by the following scores: Score Symptoms 0 complete protection 1 sporadical ventπcular extrasystoles 2 seπal ventncular extrasystoles 3 bi- and tπgeminy 4 ventπcular tachycardia 5 ventπcular fibrillation, death Table 3 Results of investigations on the antiarrhythmic effect Compound Dose (mg/kg) Route of Inhibition (%) ED, 0 (mg/kg) administration Control average score=3 9 Bisaramil 0.3 1 V 20 0 5 1 V 48 0 49 1 0 1 V 91 Quimdine 0 3 1 V 34 10 0 1 V 55 6 66 30 0 I V 83 Mexiletme 1 0 1 V 29 3 0 1 V 68 2 51 10 0 1 V 62 1 Amiodarone 3.0 iv. 13 5.0 i.v. 29 7.04 10.0 iv. 70 4600592 10 i.v. - 30 i.v. 19 - 30 p.o. 0 4611265 10 i.v. 21 30 i.v. 10 - 30 p.o. 0 4611267 10 i.v. 0 30 i.v. 29 - 30 p.o. 0 4610351 10 i.v. 16 30 i.v. 16 - 30 p.o. 5 4611266 10 i.v. 21 30 i.v. 3 - 30 p.o. 0 Note: Code numbers shown in the Tables stand for the following compounds: 4600592: known compound of formula (I) containing hydrogen as R 461 351 : compound of formula (I) containing chlorine as R 461 1 109: compound of formula (I) containing bromine as R 4610282: compound of formula (I) containing fluorine as R 4610350 compound of formula (I) containing nitro group as R 4611265 compound of formula (Ia) containing tertiary butyl groups as R and R 461 1266 compound of formula (I) containing tertiary butyl groups as R 461 1267 compound of formula (Ia) containing hydrogen as R and R' Amiodarone: (2-butyl-3-benzofuranyl)-{4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}-ketone Bisaramil: 3-methyl-7-ethyl-9α-(4-chlorobenzoyloxy)-3,7-diazabicyclo[3.3.1]nonane hydrochloride Quinidine: (S)-(6-methoxy-4-quinolinyl)-[(2R.4S.5R)-5-vinyl-2-quinuclidinyl]methanol Mexiletine: l-methyl-2-(2,6-xylyloxy)ethy]amine TRH 5-oxo-L-prolyl-L-hιstιdvl-L-prolιne amide Vinpocetine ethyl apovmcaminate Evaluation of the results When administered intravenously, aconitine ehcites a well-reproducible arrhythmia concerning both the time (duration) and seventy of effect According to the evaluations (average score = 3 9), the aconitine dose employed induced a very severe arrhythmia (ventπcular tachycardia, fibnllation) Known antiarrhythmic agents inhibited the development of arrhythmia in a dose-dependent manner The results obtained were in a good agreement with the previously published values [Orvostudomany 33, 347-361 (1982)] The compounds according to the invention did not prevent the development of aconitine anhythmia either through oral or intravenous application, 1 e the compounds of the invention did not exert any antiarrhythmic effect in the present model l-(4'-substιtuted benzyl)-4-pιpeπdones (II), used as starting mateπals can be prepared by the reactions known from the teratuere a) Starting out of 4-substιtuted benzylamines the addition of this compound on two moles acrylic acid esters, the intramolecular ester condensation and the hydrolytic decarboxylation results in compound (II) [Helv Chim Acta, 41j 1 188 (1958), J Am Chem Soc , 68, 2108 (1946)] b) Starting from 4-substιtuted benzylhalides the alkylating reaction of 4-pιpeπdone monohydrate hydrochloπde in the presence of acid binding agent yields the compound (II) [Synth Comm , 20, 3537 (1990)] The invention is illustrated in detail by the following non-limiting Examples Example 1 Preparation of the compounds of formula fl) in their free base form by spirocychsation a) A solution containing 0 22 mole of a 4-pφeπdone of formula (II) and 27 2 g (0 2 mole) of 2-hydroxyacetophenone in 100 ml of toluene was weighed into a round-bottom flask equipped with stirrer, reflux condenser and water separator device After starting the stirπng, 4 g (56 mmole) of pyrrolidine were dropped to the above mixture at room temperature After addition, the reaction mixture was heated to the boiling point and the boiling was continued for additional 2-24 hours following the gradual separation of water Then, the reaction mixture was cooled and poured into 150 ml of water After separation of the phases, the aqueous layer was re-extracted with 50 ml of toluene The combineα toluene exira . was washed with 10 ml of water and evaporated The evaporation residue of the toluene phase v. as thoroughly mixed with diisopropyl ether until crystallization and, if desired, recrystallized from a protic polar solvent, e.g. ethanol to yield 60-75 % of purified product b) 0, 1 mmole of 4-pιperidone of formula (II), 0, 1 mole 2-hydroxy-acetophenone, 0, 1 mole pirrolidine are refluxed in methanol (25 ml) solution for 3-8 hours. The progress of the reaction is controlled by TLC. After cooling the reaction mixture the compound (I) crystallize (if it does not occour during the heating period), which can be increased by colling it in the refrigerator during a night. Filtration and careful washing the filtrate cake by cold methanol yields product (I) in 80-92 % of the theoretical amount Example 2 Preparation of the compounds of formula fl) in free base form by alkylating the acid addition salt of spiro[2H-l-benzopyran-2.4'-piperidine]-4f3H)-one A mixture of 25.4 g (0.1 mole) of spiro[2H-l-benzopyran-2,4'-pιperidine]-4(3H)-one hydrochloride was boiled under reflux with 0.105 mole of a compound of formula (III) and 17 g of sodium hydrogen carbonate in 50 ml of methanol. The boiling was continued until the starting spiro[2H-l-benzopyran-2,4'-piperidine]-4(3H)-one was consumed from the reaction mixture [as detected by thin layer chromatography (TLC)], which required 4-8 hours. The compounds of formula (I) obtained could preferably be recovered from the reaction mixture as follows 1 ) After filtering the hot reaction mixture, the filter cake was thoroughly washed once with 20 ml, then twice with 10 ml of water each. The methanolic mother liquor was not combined with the washings The target compound of formula (I) was obtained in two generations one as the solid phase washed on the filter and the other one as the substance precipitating from the methanolic mother liquor in crystalline form. 2) After evaporation of the methanolic mother liquor, the residue was thoroughly mixed with water. If the target compound of formula (I) precipitated in crystalline form, it was filtered; if precipitation did not occur, the aqueous mixture was extracted with an organic solvent (such as dichloromethane) and the extract was evaporated. The target compound of formula (I) was recrystallized in each case. A Cι.j alcohol (such as methanol, ethanol or isopropanol), an ether (e.g. diisopropyl ether), an ester (such as ethyl acetate) or acetonitrile could preferably be used for this purpose. The same reagents can be used to carry out the alkylating reaction in other solvents as well, among them acetonitrile, ans isopropanol has proved the most suitable. Usually the compound of formula (I) crystallizes out of these solvents and it can be seoarated contaminated \ ->. - by inorganic salts, by filtration As compounds of formula (I) in form of free base are rather insoluble in water, the punfication can be done easily The cold organic solvents (methanol, isopropanol, acetonitrile) contain only a very limited quantity of compounds of formula (I), which can be isolated after the evaporation of the solvent and recrystallizing the remainder Example 3 Pre p aration of acid addition salts of the compounds of formula (I) a) Preparation of hydrochloπdes One mmole of a compound of formula (I) as free base was stirred in 6 ml of hydrochloπc acid solution of 0 5 mol/htre concentration at 50°C for 15 minutes After cooling (by keeping in a refrigerator for the higher yield) and filtenng the solution, if desired, the precipitated hydrochloπde was recrystallized from a protic solvent b) Preparation of hydrochloπdes One mmole of a compound of formula (I) as free base is dissolved in organic solvent, I e in ethyl acetate (20 ml) or C1-3 alcohol (10 ml) at boiling temperature To the sharp solution of compound (I) free base a small excess of solution gaseous hydrogen chloπde in the same solvent is added The precipitate is increased by cooling the solution, and filtered If it is desired the precipitate is crystallized out of organic solvents, mostly C r- , alcohol c) Preparation of hydrogen maleate salts One mmol of compound of formula (I) as free base was dissolved in an organic solvent (preferably ethanol or ether) and an ethereal solution containing 1 2 mmol of maleic acid was added After filtering off the precipitated hydrogen maleate was preferably recrystallized from ethanol The following compounds of formula (I) were prepared as described above R Salt free base Solvent of M p °C recrystalhzation Cl free base methanol 82-84 Cl hydrogen maleate ethanol 190-192 Cl hydrochloride ethanol 274-275 H free base diisopropyl ether 103-104* H hydrochlonde according a) 275 (decomp ) Br free base metnanol ' " "-Y " F free base ethanol 1 17-1 19 (CH 3 ) 3 C- free base diisopropyl ether 149-151 (CH 3 ) 3 C- hydrochloπde according Example 3 b 282-285 (decomp ) (CH 3 ) 3 C- hydrogen maleate ethanol 175-178 (CH 3 )-,C- hydrogen fϊimarate ethanol 255-258 (decomp ) * The melting point of the known compound of formula (I) containing hydrogen as R is 103- I04°C in opposition to 91-93°C published in the literature This compound could not be purified by using the method descπbed in the literature since the aimed product did not crystallize out of benzene or of a mixture of benzene and cyclohexane Example 4 Simultaneous preparation of compounds of formula fl) and quaternary salts of formula fla) from spiro[2H-l-benzopyran-2.4'-pipendine]-4(3H)-one of formula (IV) A mixture containing 2 54 g (0 01 mole) of spιro[2H-l-benzopyran-2,4'-pιpeπdιne]- 4(3H)-one hydrochloπde, 10 ml of methanol, 1 7 g of sodium hydrogen carbonate and 2 02 ml (0 01 1 mole) of 4-tertιary-butylbenzyl bromide was boiled under reflux for about 3 hours In the course of boiling the solid phase was first dissolved, then a new solid phase precipitated Subsequently, the reaction mixture was left to stand overnight in a refhgarator, then it was filtered in a cooled state The obtained solid phase (3 10 g, which melted in a wide range) was mixed with 30 ml of toluene and again filtered The obtained solid phase (1 g) was recrystallized from 25 mi of methanol to obtain 0 64 g of pure l',r-bis(4-tert-butylbenzyl)- spιro[2H-4(3H)-oxo-l-benzopyran-2,4'-pιpeπdιnιum]bromιde, m p 255-258°C After evaporation of the toluene mother liquor and recrystallization of the evaporation residue (1 97 g) from 35 ml of diisopropyl ether, 1 5 g of pure 1'- (4-tert-butylbenzyl)- spιro[2H-l-benzopyran-2,4'-pιpeπdιne]-4(3H)-one were obtained, m p 149-151°C Example 5 Preparation of quaternary salts of formula fla) from spιro[2H-l-benzopyran-2,4'- pιperιdιne]-4(3H)-one of formula (IV) A mixture containing 2 54 g (0 01 mole) of spιro[2H-l-benzopyran-2,4'-pιpeπdιne]- 4(3H)-one hydrochloride. 5 ml of methanol, 1 7 g of sodium hydrogen carbonate and 2 53 ml (0 02 mole) of benzyl chloride was boiled under reflux for 3 hours, to vield 3 66 g of 1', 1'- which was recrystallized from methanol, m p 262°C (with decomposition) Example 6 Preparation of quaternary salts of formula (Ia) from r-benzy.-spιrof2H-l-benzopyran- 2.4'-pιpeπdιne]-4f3HVones of formula fl) A mixture containing 3 07 g (0 10 mole) of l'-benzyl-spιro[2H-l-benzopyran-2,4'- pιpeπdιne]-4(3H)-one, 15 ml of methanol and 1 3 g of benzyl chloπde was boiled under reflux for 8 hours to result in 3 13 g of r, l'-dibenzyl-spiro[2H-4(3H)-oxo-l-benzopyran-2,4'- pipeπdmium] hydrochloπde, which was identical to the product of Example 5 After recrystalhzation from methanol the product melted at 262°C with decomposition Example 7 Pharmaceutical compositions a) Tablets of 100 mg weight containing 10 mg of active ingredient each Components Active ingredient 50 0 Lactose 285 0 Potato starch 100 0 Sodium dodecyl sulfate 2 5 Polyvinylpyrrolidone (Kolhdon-K 90 R ) 5 0 Microcrystalline cellulose (Avιcel R ) 50 0 Vegetable oil (Sterotex R ) 7 5 The above components were usually wet-granulated and then compressed to tablets of 100 mg weight containing 10 mg of active ingredient each b) Dragees of 125 mg weight containing 10 mg of active ingredient each The tablets prepared as descπbed above were coated in a known way by a coat consisting of sugar and talc The dragees were polished with a mixture of bee wax and carnauba wax c) Capsules containing 20 mg of active ingredient each Components g Active ingredient 40 0 Sodium lauryl sulfate 12 0 Lactose 102 0 Potato starch 102 0 1 6 After thoroughly mixing the above components, the mixture obtained was filled into hard gelatine capsules containing 20 mg of active ingredient each.

Claims: Claims 1 Spiro[2H-l-benzopyran-2,4'-pipendme]-4(3H)-one derivatives of formula (I), wherein R means halogen, nitro group or straight or branched chain Q. 6 alkyl group, and their acid addition salts, as well as their quaternary salts of formula (Ia), wherein the meanings of R and R are the same or different and are identical with said meanings of R but can represent also hydrogen, and Z " means one equivalent of an anion, exerting improving effect on dementias of vaπous pathological ongin or accompanying symptoms thereof 2 A compound of formula (I) selected from the group consisting of 1 '-(4-fluorobenzyl)-spιro[2H- 1 -benzopyran-2,4'-pιpeπdιne]-4(3H)-one, r-(4-chlorobenzyI)-spιro[2H-l-benzopyran-2,4'-pιpeπdιne]-4(3H)-one, 1 '-(4-bromobenzyl)-spιro[2H- 1 -benzopyran-2,4'-pιpendιne]-4(3H)-one, r-(4-nιtrobenzyl)-spιro[2H-l-benzopyran-2,4'-pιpeπdιne]-4(3H)-one, 1 '-(4-tert-butylbenzyl)-spιro [2H- 1 -benzopyran-2,4'-pιpeπdιne]-4(3 H)-one, and the acid addition salts thereof, as well as a compound of formula (Ia) selected from the group consisting of 1', r-bιs(4-tert-butylbenzyl)-spιro[2H-4(3H)-oxo- 1 -benzopyran-2,4'-pιpeπdιnιum]bromιde and 1', 1 '-dibenzyl- spιro[2H-4(3H)-oxo-l-benzopyran-2,4'-pιpeπdιnιum] chloπde 3 Pharmaceutical compositions exerting a improving effect on dementias of vaπous pathological origin and accompanying symptoms thereof, containing as active agent an effective dose of a spιro[2H-l-benzopyran-2,4'-pιpeπdme]-4(3H)-one deπvative of formula (I), wherein R means hydrogen, halogen, nitro group or a straight or branched chain Cι -6 alkyl group or an acid addition salt thereof, and/or a quaternary salt thereof of formula (Ia), wherein the meanings of R and R' are the same <~>r d'fVert ""r 1 ^- a -d°p.tιc?l with the ecrinα of R a* defined for the present claim, and Z " represents one equivalent of an anion, in an admixture with filling, diluting, savouring, aromatizing, stabilizing. pH-adjusting and isotonizmg as well as formulation-facilitating additives and auxiliaries usυaY employed for the preparation of such compositions 4 Process for the preparation of novel spιro[2H-l-benzopyran-2,4'-pιpeπdιne]-4(3H)- one deπvatives of formula (I), wherein R means halogen, nitro group or a straight or branched chain Cι. 6 alkyl group, and acid addition salts thereof, as well as their quaternary salts of formula (Ia), wherein the meanings of R and R' are the same or different and are identical with the meanings of R but can represent also hydrogen, and Z " means one equivalent of an anion, exerting improving effect on dementias of vaπous pathological ongm and accompanying symptoms thereof, which c o m p r i s e s a) reacting o-hydroxyacetophenone with an N-(p-substιtuted benzyl)-4-pιpeπdone deπvative of formula (II), wherein R stands for halogen or nitro group or a straight or branched chain Cι.β alkyl group, in the presence of pyrrolidine, or b) alkylating spιro[2H-l-benzopyran-2,4'-pιpeπdιne]-4(3H)-one of formula (TV) with a p-substituted benzyl halide of formula (III), wherein R means halogen or nitro group or a straight or branched chain Cι.β alkyl group, and X stands for chloπne or bromine, in the presence of an acid binding agent, then if desired, converting a spιro[2H-l-benzopyran-2,4'-pιpeπdιne]-4(3H)-one deπvative of formula (I), wherein R means halogen or nitro group or a straight or branched chain Cw alkyl group obtained by process a) and/or b) in the base form thereof, to its acid addition salt by treating it with an acid, and/or, if desired, liberating the base form of a spιro[2H-l-benzopyran-2,4'- pιpendιne]-4(3H)-one denvative of formula (I), wherein R means halogen or nitro group or a straight or branched chain Cι- 6 alkyl group obtained as an acid addition salt by treating it with a base, or c) quaternizing a spιro[2H-l-benzopyran-2,4'-pιpeπdιne]-4(3H)-one deπvative of formula (IV) or an acid addition salt thereof, or a spiro[2H-l-benzopyran-2,4'-pipendme]- 4(3H)-one deπvative of formula (I) or an acid addition salt thereof, wherein R means hydrogen, halogen, nitro group or a straight or branched chain Cι-6 alkyl group, with a benzyl halide of formula (III), wherein R means hydrogen, halogen or nitro group or a straight or branched chain Cι-6 alkyl group, and X represents chloπne or bromine, to obtain quaternary salts of formula (Ia), w herein the meanings of R and R are the ' different ar.„ are identical with the Oi out can mean also hydrogen, and Z " means one equivalent of an anion 5 Process for the preparation of pharmaceutical compositions exerting an improving effect on dementias of various pathological oπgin and accompanying symptoms thereof, which c o m p r i s e s mixing as active agent an effective dose of a spιro[2H-l-benzopyran-2,4'- pιpendme]-4(3H)-one deπvative of formula (I), wherein R means hydrogen, halogen or nitro group or a straight or branched chain alkyl group, or a pharmaceutically acceptable acid addition salt thereof, and/or of a quaternary salt thereof of formula (Ia), wherein the meanings of R and R' are the same or different and are identical with the meanings of R as defined for the present claim, with filling, diluting, savouring, aromatizing, stabilizing, pH-adjust g and isotonizing as well as formulation-facilitating additives and auxiliaries usually employed for the preparation of such compositions and transforming them to a pharmaceutical composition. 6. A method of treatment for improving dementias of various pathological oπgin and accompanying symptoms thereof on mammals including man, c h a r a c t e r i z e d by administeπng to the mammal including man to be treated an effective dose of a spιro[2H-l- benzopyran-2,4'-pιpeπdine]-4(3H)-one deπvative of formula (I), wherein R means hydrogen, halogen, nitro group or a straight or branched chain alkyl group, or a pharmaceutically acceptable acid addition salt thereof; and/or of a quaternary salt thereof of formula (Ia), wherein the meanings of R and R' are the same or different and are identical with the meanings of R as defined for the present claim, alone or in the form of a pharmaceutical composition

Inventors: BORZA ISTVAN, CSOMOR KATALIN, FARKAS SANDOR, GERE ANIKO, HARSANYI KALMAN, HORVATH CSILLA, KARPATI EGON, KISS BELA, KIS-VARGA AGNES, LAPIS ERZSEBET, LASZLOVSZKY ISTVAN, LASZY JUDIT, PELLIONISZ MARGIT, SZABADKAI ISTVAN, SZABO SANDOR, BORZA, ISTVAN, CSOMOR, KATALIN, FARKAS, SANDOR, GERE, ANIKO, HARSANYI, KALMAN, HORVATH, CSILLA, KARPATI, EGON, KISS, BELA, KIS-VARGA, AGNES, LAPIS, ERZSEBET, LASZLOVSZKY, ISTVAN, LASZY, JUDIT, PELLIONISZ, MARGIT, SZABADKAI, ISTVAN, SZABO, SANDOR
Applicants: BORZA ISTVAN, CSOMOR KATALIN, FARKAS SANDOR, GERE ANIKO, HARSANYI KALMAN, HORVATH CSILLA, KARPATI EGON, KIS VARGA AGNES, KISS BELA, LAPIS ERZSEBET, LASZLOVSZKY ISTVAN, LASZY JUDIT, PELLIONISZ MARGIT, RICHTER GEDEON VEGYESZET, SZABADKAI ISTVAN, SZABO SANDOR, BORZA, ISTVAN, CSOMOR, KATALIN, FARKAS, SANDOR, GERE, ANIKO, HARSANYI, KALMAN, HORVATH, CSILLA, KARPATI, EGON, KISS, BELA, KIS-VARGA, AGNES, LAPIS, ERZSEBET, LASZLOVSZKY, ISTVAN, LASZY, JUDIT, PELLIONISZ, MARGIT, RICHTER GEDEON VEGYESZETI GYAR RT., SZABADKAI, ISTVAN, SZABO, SANDOR
Application year: 1997
Main classification: A61K
IPC codes: A61K31, A61P25, C07D491